 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...90919293949596979899100...143144» |
- || duligotuzumab (MEHD7945A) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, P2 data, Journal, Combination therapy: Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer. (Pubmed Central) - Dec 24, 2019
Duligotuzumab plus FOLFIRI did not appear to improve the outcomes in patients with RAS exon 2/3 wild-type mCRC compared to cetuximab + FOLFIRI.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: STAT3/HOTAIR signaling axis regulates HNSCC growth in an EZH2-dependent manner. (Pubmed Central) - Dec 24, 2019
Our results suggest that STAT3 signaling promotes HNSCC progression via regulating HOTAIR and pEZH2-S21 in HNSCC with PI3K overexpression/activation. These findings provide a rationale to target the STAT3/HOTAIR/pEZH2-S21 regulatory axis for treating patients with HNSCC.
- || Clinical, Journal: Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. (Pubmed Central) - Dec 23, 2019
P2
The results of the PRODIGE18 (Partenariat de Recherche en Oncologie DIGEstive) study showed a nonsignificant difference but favored continuation of bevacizumab with chemotherapy crossover for patients with wild-type RAS metastatic colorectal cancer that progressed with first-line bevacizumab plus chemotherapy. ClinicalTrials.gov identifier: NCT01442649 and clinicaltrialsregister.eu identifier: EUDRACT 2009-012942-22.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
Clinical, P2 data, Retrospective data, Journal: Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. (Pubmed Central) - Dec 23, 2019
P2
The evaluation of RAS mutational status on ctDNA might be helpful in selecting candidate patients. ClinicalTrials.gov Identifier: NCT02296203.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Journal, HEOR: Cost-effectiveness of nivolumab in the treatment of head and neck cancer. (Pubmed Central) - Dec 23, 2019
ClinicalTrials.gov Identifier: NCT02296203. At current prices nivolumab has an ICER of around CHF 100,000 per QALY gained in the second line treatment of r/mHNSCC patients in Switzerland.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Vizimpro (dacomitinib) / Pfizer
Journal: The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. (Pubmed Central) - Dec 23, 2019
At current prices nivolumab has an ICER of around CHF 100,000 per QALY gained in the second line treatment of r/mHNSCC patients in Switzerland. Our findings indicate that dacomitinib-mediated blockade of the ERBB receptors yields advantages over single-targeted ERBB inhibition and provide a rationale for further investigation of the therapeutic potential of dacomitinib in the treatment of ERBB-driven PDAC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Systemic therapy for advanced cutaneous squamous cell carcinoma. (Pubmed Central) - Dec 23, 2019
Despite these advances, the preferred regimen for systemic treatment of cSCC remains unclear, particularly in immunocompromised populations. Herein we provide a review of the literature supporting the use of these modalities and a discussion of their clinical utility.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Alpha-Gal-containing biologics and anaphylaxis. (Pubmed Central) - Dec 23, 2019
Investigations of cetuximab-related anaphylaxis have revealed three novel findings that improve our understanding of immediate-type allergy: 1) oligosaccharide can serve as the main IgE epitope of anaphylaxis; 2) because of the oligosaccharide epitope, a wide range of cross-reactivity with mammalian meats containing α-Gal similar to cetuximab occurs; and 3) tick bites are a crucial factor of sensitization to the oligosaccharide. Nonetheless, taking a medical history of tick bites and beef allergy may be insufficient to prevent cetuximab-induced anaphylaxis, and therefore blood testing with an α-Gal-specific IgE test, with high sensitivity and specificity, is necessary to detect sensitization to α-Gal.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
PK/PD data, Journal, HEOR: An evaluation of cetuximab dosing strategies using pharmacokinetics and cost analysis. (Pubmed Central) - Dec 23, 2019
Nonetheless, taking a medical history of tick bites and beef allergy may be insufficient to prevent cetuximab-induced anaphylaxis, and therefore blood testing with an α-Gal-specific IgE test, with high sensitivity and specificity, is necessary to detect sensitization to α-Gal. Cost-effectiveness of cetuximab treatment can be improved with alternative strategies by reducing wastage without compromising exposure.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, HEOR: Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer. (Pubmed Central) - Dec 23, 2019
Indirect costs accounted for 65% in both scenarios. The adoption of an EOW administration schedule of cetuximab reduced direct and indirect costs substantially.
- | fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: In Vitro Assessment of Antitumor Potential and Combination Effect of Classical and Molecular-targeted Anticancer Drugs. (Pubmed Central) - Dec 22, 2019
The adoption of an EOW administration schedule of cetuximab reduced direct and indirect costs substantially. The present TS monitoring system may provide useful information for building up the treatment regimens of anticancer drugs.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical, Review, Journal, Combination therapy: Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. (Pubmed Central) - Dec 22, 2019
Herein we provide updates in treatment options for patients with BRAF V600E-mutant mCRC, focusing on the practice-changing BEACON-triplet regimen, the first chemotherapy-free combination regimen for mCRC. This combination is being explored frontline in the ANCHOR clinical trial.
- || oxaliplatin / Generic mfg., fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, HEOR: Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer. (Pubmed Central) - Dec 22, 2019
P3
Sensitivity analysis showed that the cost of PFS in the cetuximab plus FOLFOX-4 arm was the most influential factor in the Markov model. The combination of cetuximab and FOLFOX-4 is not a cost-effective strategy compared with FOLFOX-4 alone for the first-line treatment of patients with RAS wt mCRC from the perspective of Chinese society.
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data: Phase 2 , can be done,7-10% nonclassical mutation are better than 1-3 % of BRAF,RET,HER2 for whom single phase 2 trial may still be acceptable compared to historical cohort of chemotherapy. E.g BEACON trial done in colon against cetuximab (Twitter) - Dec 22, 2019
- cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
A phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer. (Poster Board H14) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_1228;
Although recruitment failed to reach the pre-specified target for phase 2 exploratory analysis indicate the 3 month bladder control rates and recurrence rates are above those reported in BC2001 with good PROMs provides evidence to consider further evaluation of cetuximab. Clinical trial information: 80733590.
- cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
A phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer. (Poster Board H14) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_946;
Although recruitment failed to reach the pre-specified target for phase 2 exploratory analysis indicate the 3 month bladder control rates and recurrence rates are above those reported in BC2001 with good PROMs provides evidence to consider further evaluation of cetuximab. Clinical trial information: 80733590.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis. (Pubmed Central) - Dec 21, 2019
Although limited by small numbers, the combination of cetuximab and radiotherapy in CSCC appears well tolerated there were more long-term survivors and less distant metastasis in the cetuximab group. These promising finding warrant further studies.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease. (Pubmed Central) - Dec 21, 2019
Among patients with p16-positive OPSCC with low-neck and/or N3 lymphadenopathy, ICT followed by CCRT may reduce the risk for distant failure over CCRT alone and lead to improved progression-free survival. Future trials should concentrate on patients at the highest risk of distant metastasis in order to appropriately assess the benefit of ICT.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPVstatus in head and neck cancer. (Pubmed Central) - Dec 21, 2019
Future trials should concentrate on patients at the highest risk of distant metastasis in order to appropriately assess the benefit of ICT. Our findings suggest a novel role of STING in HPV-related carcinogenesis, in which activation of the STING signaling pathway may facilitate anti-tumor response in HNSCC patients, particularly in combination with therapeutic monoclonal antibodies (mAbs) such as cetuximab, an epidermal growth factor receptor (EGFR) inhibitor.
- || cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Clinical data, Journal: Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma. (Pubmed Central) - Dec 21, 2019
When treating p16+ OPC with CRT, the threshold for substitution of cisplatin with cetuximab should be maintained appropriately high in order to prolong survival times and optimize locoregional and distant tumor control. When cetuximab is used in cisplatin-ineligible patients, altered fractionation RT should be considered in an effort to improve LRC.
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Combination therapy: Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma. (Pubmed Central) - Dec 21, 2019
Patients undergoing IC plus CCRT suffered from severe hematologic toxicity and diarrhea compared with those treated with CTX/NTZ plus CCRT. The combination of CTX/NTZ with CCRT is comparable to IC plus CCRT treatment in survival outcomes for locoregionally advanced NPC patients but has a better safety profile than IC plus CCRT treatment.
- || fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic mfg.
Retrospective data, Review, Journal: Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options. (Pubmed Central) - Dec 21, 2019
In terms of OS Concurrent chemoradiotherapy (CCRT) with cisplatin (HR 0.70, 95% CrI [credible interval] 0.62-0.78) and cetuximab on top of CCRT (HR 0.7, 95% CrI 0.5-0.97) are clearly superior to conventional RT alone...Regarding PFS, CCRT with cisplatin (HR 0.72, 95% CrI 0.63-0.83), cisplatin and fluorouracil (HR 0.67, 95% CrI 0.5-0.88), carboplatin (HR 0.63, 95% CrI 0.46-0.87), carboplatin and fluorouracil (HR 0.75, 95% CrI 0.56-1), IC with cisplatin and fluorouracil (HR 0.59, 95% CrI 0.45-0.78), IC with docetaxel, cisplatin and fluorouracil (HR 0.53, 95% CrI 0.41-0.68) and IC with paclitaxel, cisplatin and fluorouracil (HR 0.59, 95% CrI 0.35-0.99) are superior to conventional RT and altered fractionation RT...Altered fractionation RT is inferior to CCRT and also does not seem to be meaningfully better than conventionally fractionated RT alone. Its role in locally advanced disease should be reevaluated.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Biomarker, Clinical, P2 data, Journal, Gene Signature: Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. (Pubmed Central) - Dec 21, 2019
Despite differences in clinical settings and anti-EGFR inhibitors used for treatment, response prediction by the Cluster3 signature and selected miRNAs was essentially the same. Translation into a useful clinical assay requires validation in a broader setting.
- || cixutumumab (IMC A12) / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, P2 data, Journal: Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. (Pubmed Central) - Dec 21, 2019
Translation into a useful clinical assay requires validation in a broader setting. The results of this study do not support the use of cixutumumab alone or with cetuximab in unselected patients with R/M HNSCC.
- || oxaliplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy. (Pubmed Central) - Dec 21, 2019
The results of this study do not support the use of cixutumumab alone or with cetuximab in unselected patients with R/M HNSCC. In a large cohort of well-defined stage III CC patients, CIMP+ phenotype is associated with a shorter OS and SAR but not to DFS.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Monotherapy: Tumor spontaneous regression in an elderly patient with Squamous Cell Carcinoma of the cranial vertex pre-treated with cetuximab monotherapy. (Pubmed Central) - Dec 21, 2019
SCC incidence is increasing mainly as a result of ultraviolet radiation exposure and aging. Also immunosuppression represents a risk factor for its development.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy. (Pubmed Central) - Dec 21, 2019
The prognostic role of TAM phenotype and distribution depends on HPV status and might predict treatment response. They prompt further validation in prospective studies.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Reimbursement, Journal, Medicare: Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. (Pubmed Central) - Dec 21, 2019
They prompt further validation in prospective studies. Despite the limitations to comparative effectiveness evaluation in population-based registries, our data suggest that cytotoxic chemotherapy should be used with RT for eligible older HNSCC patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab. (Pubmed Central) - Dec 21, 2019
The internalization and pro-EMT effects of the OSCC-EVs were largely blocked by cetuximab. Thus, OSCC-derived EVs transform normal epithelial cells into a mesenchymal phenotype and anti-EGFR therapeutic antibody cetuximab inhibits such a carcinogenic effect of the OSCC-EVs.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. (Pubmed Central) - Dec 21, 2019
Mechanistically, we showed that the overexpression of HER2 and HER3 following cetuximab treatment is mediated by the ETS homologous transcription factor (EHF), and is suppressed by MET/MAPK pathway activation. Collectively, our findings indicate that evaluation of MET and HER2/HER3 in response to cetuximab in HNSCC patients can provide the rationale of successive line of treatment.
- || cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: In HPV-associated oropharyngeal cancer, chemoradiotherapy with cisplatin is superior to bioradiotherapy with cetuximab in terms of overall survival (Pubmed Central) - Dec 20, 2019
Collectively, our findings indicate that evaluation of MET and HER2/HER3 in response to cetuximab in HNSCC patients can provide the rationale of successive line of treatment. No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Dec 20, 2019
In this work, the authors showed that Zr-DFO-cetuximab is suitable for identification of EGFR downregulation in vitro and in vivo. This radiopharmaceutical may be useful for monitoring resistance in HNSCC patients during cetuximab therapy.
- | Mekinist (trametinib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib. (Pubmed Central) - Dec 20, 2019
Both cetuximab and gefitinib in combination with trametinib produced an additive effect in all EGFR sensitive cell lines. Our results indicate that mesothelin and TGF-α can predict PDAC sensitivity to EGFR inhibitors and a combination of EGFR inhibitors with trametinib could be a novel effective treatment for PDAC.
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
An Open-label, Non-randomized, Multi-arm, Phase II Trial Evaluating Pembrolizumab Combined with Cetuximab in Patients (pts) with Recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Updated Results of Cohort 1 Analysis (The Westin Kierland Resort and Spa) - Dec 20, 2019 - Abstract #MHNCS2020MHNCS_52;
P2
Further exploration of efficacy analysis as a function of PD-L1 expression status is warranted. NCT03082534.
- cisplatin / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Long-Term Update of NRG Oncology RTOG 0522: A Randomized Phase III Trial of Concurrent Radiation and Cisplatin with or without Cetuximab in Locoregionally Advanced Head and Neck Cancer (The Westin Kierland Resort and Spa) - Dec 20, 2019 - Abstract #MHNCS2020MHNCS_19;
NCT03082534. With a median follow-up of over 10 years, this updated report confirms the addition of cetuximab to RT+cisplatin did not improve any measured outcome in the entire cohort, or when stratifying by p16-status.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2/3 data, Journal: Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer. (Pubmed Central) - Dec 20, 2019
However, in the context of cisplatin ineligible patients, cetuximab should be used only with hyper fractionation. This preliminary study could represent a good core of large international multicenter RCT.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer? (Pubmed Central) - Dec 19, 2019
The RAS-mutation status is not predictive for VEGF-inhibitors. Recent developments in the molecular characterisation of tumor cells led to the development of specific so called targeted therapies in colorectal cancer.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Validation of the 8 edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy. (Pubmed Central) - Dec 19, 2019
The new 8 Ed UICC/AJCC TNM staging system better discriminates between stage I and Stage II HPV OPSCC with respect to OS compared with the 7 Ed staging system. Further investigation is required for stage III or IV patients.
- ||| fluorouracil / Generic mfg., Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P3 data, Clinical Trial,Phase III, Journal, PD(L)-1 Biomarker, IO Biomarker: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. (Pubmed Central) - Dec 19, 2019
P3
Further investigation is required for stage III or IV patients. Based on the observed efficacy and safety, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for recurrent or metastatic HNSCC and pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, Tumor Mutational Burden, IO Biomarker: Update on HPV-associated head and neck cancer-highlights from the 2019 ASCO Annual Meeting (Pubmed Central) - Dec 19, 2019
P2
Modification seems to have a positive impact on the success of therapy. However, robust data are still lacking for the various modified treatments for HPV-associated OPSCC, which are needed before their implementation in daily practice.
- || fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting (Pubmed Central) - Dec 19, 2019
Based on the results of Keynote-048, pembrolizumab ± chemotherapy gained FDA approval as first-line treatment for R/M-HNSCC in the USA. Approval in Europe is expected soon and will probably have a strong impact on clinical routine.
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
FDA event, sNDA, Combination therapy: U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy | Business Wire https://t.co/GNAQOOasTN (Twitter) - Dec 19, 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date: Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) (clinicaltrials.gov) - Dec 17, 2019
P2, N=27, Completed, Sponsor: Stanford University
Approval in Europe is expected soon and will probably have a strong impact on clinical routine. Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Aug 2019
- |||| LY3499446 / Eli Lilly
Enrollment open, Metastases: A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation (clinicaltrials.gov) - Dec 17, 2019
P1/2, N=230, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Aug 2019 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Je pense que c'est assez clair hein président !!! Nous sommes tous ( jeunesse ivoirienne ) mobilisé pour le grand retour. Ya dieu dedans 👌 @GPS @CP @GSK @CI225 (Twitter) - Dec 16, 2019
- | fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Identification of the optimal cetuximab concentration that is effective against oral squamous cell carcinoma in collagen gel droplet embedded culture drug sensitivity testing. (Pubmed Central) - Dec 15, 2019
The CD-DST method is suitable for evaluating and selecting chemotherapy regimens, including molecularly targeted drugs. Future studies are required to generate and evaluate relevant clinical data.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination: Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum (clinicaltrials.gov) - Dec 13, 2019
P2, N=6, Terminated, Sponsor: University of Wisconsin, Madison
Future studies are required to generate and evaluate relevant clinical data. Completed --> Terminated; Loss of funding
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) (clinicaltrials.gov) - Dec 12, 2019
P2, N=172, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated; Loss of funding Trial completion date: Jan 2020 --> Jan 2021
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) (clinicaltrials.gov) - Dec 12, 2019
P3, N=495, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jan 2020 --> Jan 2021 Trial completion date: Jan 2020 --> Jan 2021
- || Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) (clinicaltrials.gov) - Dec 11, 2019
P1, N=10, Completed, Sponsor: The Netherlands Cancer Institute
Trial completion date: Jan 2020 --> Jan 2021 Active, not recruiting --> Completed